Frances A. Wier, CNM, MS, is a staff nurse-midwife at Mercy Medical Center located in Baltimore, Maryland.
Clinical Controversies in Screening Women for Thyroid Disorders During Pregnancy
Article first published online: 24 DEC 2010
2006 American College of Nurse Midwives
Journal of Midwifery & Womens Health
Volume 51, Issue 3, pages 152–158, May-June 2006
How to Cite
Wier, F. A. and Farley, C. L. (2006), Clinical Controversies in Screening Women for Thyroid Disorders During Pregnancy. Journal of Midwifery & Womens Health, 51: 152–158. doi: 10.1016/j.jmwh.2005.11.007
- Issue published online: 24 DEC 2010
- Article first published online: 24 DEC 2010
- subclinical hypothyroidism;
- thyroid peroxidase antibody;
Subclinical hypothyroidism and/or the presence of thyroid peroxidase antibodies (TPOAb) may be associated with subfertility, infertility, spontaneous abortion, placental abruption, preterm delivery, gestational hypertension, preeclampsia, postpartum thyroid dysfunction, depression (including postpartum depression), and impaired cognitive and psychomotor child development. In November 2002, the American Association of Clinical Endocrinologists (AACE) released new guidelines for clinical practice for the diagnosis and treatment of hyperthyroidism and hypothyroidism, which includes a new thyroid-stimulating hormone (TSH) reference range of 0.3 to 3.0 mIU/L. Recently, the AACE recommended screening all women considering conception and/or all gravid women in the first trimester for thyroid dysfunction. However, the American College of Obstetricians and Gynecologists (ACOG) and the United States Preventive Services Task Force (USPSTF) have not endorsed these recommendations. This article reviews the evidence regarding screening women during pregnancy for subclinical hypothyroidism and/or the presence of thyroid peroxidase antibodies.